How Much Did Evogene Raise?
Funding & Key Investors

Evogene has secured significant enterprise-level funding, with its most recent capital infusion being a major strategic investment. The total funding amount raised by the company stands at $15M, underscoring its substantial financial backing and growth trajectory. The recent funding round, which occurred on September 1, 2020, highlights continued investor confidence in Evogene's innovative approach to life-science product development.

What is Evogene?

Evogene
Business ServicesResearch & Development

Founded in 1999 and headquartered in Rehovot, Israel, Evogene is a pioneering computational biology company. It leverages its proprietary AI-driven technological engines, including MicroBoost AI, ChemPass AI, and GeneRator AI, to accelerate the discovery of novel products in the fields of microbes, small molecules, and genetic elements. The company's platforms are applied across critical sectors such as human therapeutics, ag-chemicals, and industrial-scale agriculture, often in collaboration with its subsidiaries and strategic partners. This AI-centric model positions Evogene at the forefront of innovation in the life sciences.

How much funding has Evogene raised?

Evogene has raised a total of $15M across 2 funding rounds:

2013

Stock Offering

$5M

2020

Share Placement

$10M

Stock Issuance/Offering (2013): $5M, investors not publicly disclosed

Share Placement (2020): $10M led by ARK Investment Management LLC and Alpha Capital Anstalt

Key Investors in Evogene

ARK Investment Management LLC

ARK Investment Management LLC is a prominent investment firm known for its focus on disruptive innovation and technology-driven growth sectors, suggesting a strategic alignment with Evogene's AI-centric approach.

Alpha Capital Anstalt

Alpha Capital Anstalt is an investment entity that likely seeks opportunities in companies with strong technological foundations and significant market potential, aligning with Evogene's computational biology and AI platforms.

What's next for Evogene?

The substantial enterprise-level funding and recent strategic investment indicate that Evogene is poised for significant expansion and further development of its AI-driven platforms. This capital infusion will likely fuel advancements in its core technologies and accelerate the commercialization of its life-science based products across therapeutics, ag-chemicals, and agriculture. Evogene's focus on computational biology and AI suggests a strategic direction aimed at disrupting traditional discovery processes and capturing market share in high-growth sectors.

See full Evogene company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Business Services industry

Business ServicesSoftware TestingSoftwareIndustrial Machinery & EquipmentManufacturingHealthcare Software
Accounting for Legal PracticesBusiness Services
Business ServicesHuman Resources Management Systems (HRMS)Accounting for Legal Practices
Business ServicesSoftware TestingConsumer ServicesRepair Services

Frequently Asked Questions Regarding Evogene Financial Insights

What are the most recent funding rounds that Evogene has completed, and what were the funding rounds?
Evogene has recently completed 2 funding rounds: Share Placement on Sep 1, 2020, Stock Offering on Nov 20, 2013.
What is the total amount of funding Evogene has raised to date?
Evogene has raised a total of $15M in funding to date.
How many funding rounds has Evogene completed?
Evogene has completed 2 funding rounds.
How much funding did Evogene raise in its most recent funding round?
Evogene raised $10M in its most recent funding round.
Who are the lead investors in Evogene's latest funding round?
The lead investor in Evogene's latest funding round was ARK Investment Management LLC. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in Evogene's history?
The largest funding round in Evogene's history was $10M.
See more information about Evogene